Levels BBB and Consumer-Complaint Trends: What the Data Actually Show

What Is Levels Health and How Does Its Model Work?

Levels Health markets itself as a metabolic-health coaching platform built around continuous glucose monitor data. Subscribers receive a CGM sensor (Abbott FreeStyle Libre or Dexcom G7), access to a companion app that interprets glucose trends, and optional access to clinician messaging. The model is hybrid: the device is FDA-regulated, the software interpretation layer is not regulated as a medical device under current FDA enforcement discretion policy, and the coaching content is wellness rather than clinical care.

The FDA Device Layer

CGMs cleared by the FDA are Class II devices. Abbott's FreeStyle Libre 3 received 510(k) clearance (K213328) and the Dexcom G7 received clearance (K221867). Both are listed in the FDA 510(k) database. Adverse events tied to cleared CGM devices are captured in the FDA's Manufacturer and User Facility Device Experience (MAUDE) database, which is publicly searchable and shows thousands of sensor-adhesion, calibration-drift, and skin-irritation reports across all CGM brands, not specific to Levels as a distributor.

The Software and Coaching Layer

The Levels app processes CGM data and generates metabolic scores. The FDA's 2019 Digital Health Software Precertification Program guidance and the 21st Century Cures Act carve out certain wellness software from device regulation. Whether Levels' scoring algorithms cross the line into clinical decision support is a live regulatory question. The FDA's Software as a Medical Device (SaMD) guidance defines the risk-based framework used to evaluate such products.

BBB Filing Patterns for Levels Health

The Better Business Bureau serves as a first-pass consumer-complaint aggregator for subscription businesses. Levels' BBB profile (as of the date of this review) shows complaints concentrated in three categories: difficulty canceling subscriptions, unexpected automatic-renewal charges, and delays in receiving CGM hardware after payment.

Billing and Cancellation Complaints

Subscription-trap patterns are the single most common BBB complaint category for direct-to-consumer health tech. The FTC has taken enforcement action under Section 5 of the FTC Act against companies that make cancellation "unreasonably difficult," as outlined in the FTC's Negative Option Rule final amendments (2023). Levels uses an auto-renewing membership structure. Prospective subscribers should read cancellation terms in full before entering payment information.

Hardware Fulfillment Complaints

Several BBB filings describe paying for a membership tier that includes a CGM sensor, then waiting two to four weeks for hardware to ship. CGMs require a valid prescription in most states. Fulfillment delays at the prescriber-pharmacy interface are a documented friction point in telehealth CGM programs, not unique to Levels but worth noting as a pattern in their complaint record.

Resolution Rate

BBB resolution rate matters more than raw complaint volume for a business of Levels' size. A high closure-with-resolution rate suggests responsive customer service even when complaints are filed. Consumers can verify the current resolution status directly at bbb.org by searching "Levels Health."

Is Levels Legit? Regulatory and Verification Signals

"Legit" in the context of a telehealth-adjacent subscription company means four things: licensed prescribers, FDA-compliant devices, transparent billing, and accurate advertising claims. Each deserves separate evaluation.

Licensed Prescribers

CGMs in the United States require a prescription from a licensed clinician. Levels uses contracted telehealth physicians to issue those prescriptions. The applicable standard is each state's telemedicine practice act. The Federation of State Medical Boards publishes model telemedicine policy guidance that most state boards have adopted in some form. A prescriber who issues a CGM order without an adequate clinical evaluation may be in violation of state medical board rules. Consumers can verify prescriber licensure through their state medical board's public lookup tool.

FDA Device Compliance

Levels does not manufacture CGM sensors. It distributes or facilitates access to FDA-cleared devices from Abbott and Dexcom. That means FDA device-safety accountability sits primarily with the manufacturers, not with Levels. The FDA's medical device reporting regulations at 21 CFR Part 803 require manufacturers to submit adverse-event reports, which is why MAUDE data reflects Abbott and Dexcom filings rather than Levels-specific filings.

LegitScript Certification Status

LegitScript is the primary third-party certification body for online health and pharmacy operations. As of the date of this review, Levels Health does not appear in LegitScript's certified merchant database. LegitScript certification is not legally required, but its absence means the company has not undergone LegitScript's independent review of prescribing practices, pharmacy compliance, and advertising claims. That is a neutral finding, not a disqualifying one, but it limits independent verification.

FTC Advertising Standards

The FTC's health claims guidance requires that testimonials and endorsements reflect typical consumer results. CGM-based weight-loss or metabolic-improvement claims must be substantiated. The scientific record on CGM use in non-diabetic populations is still developing. A 2023 study published in JAMA Internal Medicine found that CGM feedback alone produced modest glycemic improvements in adults without diabetes but did not demonstrate clinically significant weight loss as a standalone intervention.

What the Science Says About CGM in Metabolic Health (Non-Diabetic Use)

Levels markets CGM data as a tool for metabolic optimization in people who do not have diabetes. That claim sits in contested clinical territory. Understanding the evidence helps consumers evaluate whether the product delivers on its promises.

Glycemic Variability and Metabolic Risk

Glycemic variability (GV) is the degree to which blood glucose fluctuates over time. Elevated GV in non-diabetic adults has been associated with increased cardiovascular risk markers in observational data. A 2021 study in Diabetes Care found that higher time-above-range on CGM correlated with subclinical atherosclerosis markers in a cohort of 500 adults without diagnosed diabetes. That is an association, not proof of causation, and CGM-guided behavior change has not been tested in a randomized trial powered for cardiovascular outcomes in this population.

CGM Accuracy in Non-Diabetic Ranges

CGM sensors are calibrated and validated primarily in diabetic ranges (roughly 70 to 400 mg/dL). In healthy adults, glucose rarely exceeds 140 mg/dL postprandially. Abbott's FreeStyle Libre 3 clinical validation data (submitted to FDA under K213328) showed a mean absolute relative difference (MARD) of approximately 7.9% across the full labeled range. At glucose values below 100 mg/dL, sensor error as a percentage of true glucose is proportionally larger. This matters for interpreting the "metabolic scores" Levels generates from that raw sensor data.

Behavior Change Evidence

The hypothesis underlying Levels is that seeing real-time glucose data motivates healthier food choices. A 2022 randomized controlled trial in The Lancet Digital Health assigned 156 adults without diabetes to CGM-guided dietary coaching versus standard dietary advice and found no statistically significant difference in HbA1c at 16 weeks (P = 0.21). CGM-guided participants did reduce processed carbohydrate intake, but the clinical significance of that dietary shift was not sustained at 12-month follow-up. That single trial does not settle the question, but it illustrates the gap between the promise of real-time biofeedback and demonstrated clinical outcomes.

Consumer-Complaint Trends Across Review Platforms

BBB is one data source. Cross-referencing it with Trustpilot, Reddit (r/diabetes and r/biohacking), and Apple App Store reviews gives a fuller picture of what actual users report.

Common Positive Feedback

Users who report satisfaction typically cite the app's food-logging interface, the visual glucose-curve display, and the sense of motivation that comes from seeing postprandial spikes. These are real usability signals, not clinical outcomes.

Common Negative Feedback

Negative reviews cluster around four issues. First, the subscription is expensive relative to what is clinically established. Second, canceling requires a phone or chat interaction rather than a self-service button, which maps directly to FTC Negative Option Rule concerns. Third, some users report that the metabolic score algorithm changes with app updates, making longitudinal trend data hard to interpret. Fourth, a minority of users report skin reactions at the CGM adhesion site, which is a known device-class issue documented in MAUDE reports for Abbott Libre products.

Contextualizing Complaint Volume

Raw complaint count must be normalized by subscriber volume. Levels has not publicly disclosed subscriber counts. A company with 100,000 subscribers and 200 BBB complaints has a complaint rate of 0.2%, which is low. The same 200 complaints across 5,000 subscribers represents a 4% complaint rate, which is high. Without denominator data, absolute complaint counts are difficult to interpret. This is a systemic limitation of BBB data for private companies.

Billing Practices and the FTC Negative Option Framework

Subscription health companies face specific FTC scrutiny. The FTC finalized amendments to its Negative Option Rule in 2023, requiring that cancellation be "at least as easy as enrollment." Companies must offer a simple mechanism, such as a single click or a brief online form, to cancel any subscription initiated online.

The framework below summarizes what to verify before subscribing to any CGM-based health platform:

1. Cancellation pathway. Can you cancel through the same channel used to sign up? If enrollment is online but cancellation requires a phone call, that is a potential Negative Option Rule violation.
2. Auto-renewal disclosure. Is the renewal date, price, and cancellation deadline disclosed clearly before you enter payment details, not buried in terms of service?
3. Prescription process. Who is prescribing the CGM? Can you verify that clinician's license through your state medical board?
4. Device provenance. Are the CGM sensors FDA-cleared? Request the 510(k) number or NDC code if uncertain.
5. Refund policy. Is there a prorated refund for unused subscription days? Policies that offer no refund on annual plans may face state consumer-protection challenges depending on jurisdiction.

The FTC's Negative Option Rule final rule (16 CFR Part 425) is the governing federal standard. Several state attorneys general, including California (under the Automatic Renewal Law, Cal. Bus. & Prof. Code section 17600) and New York, have parallel statutes with broader private rights of action.

How Levels Compares to Other CGM Subscription Models

Levels is not alone in the CGM-subscription space. Signos, January AI, and NutriSense operate similar models. Each involves FDA-cleared hardware bundled with proprietary software interpretation and a subscription fee.

Regulatory Positioning

None of these platforms are FDA-approved as medical devices for the metabolic-coaching use case they advertise. They operate under wellness and general-wellness software carve-outs. The FDA's General Wellness Policy (2019) defines low-risk wellness devices as those that "do not make references to diseases or conditions." Platforms that describe glucose spikes as linked to insulin resistance, prediabetes risk, or cardiovascular outcomes may be edging outside the wellness carve-out. The FDA has not publicly cited any of these companies, but the regulatory line is narrow.

Clinical Supervision Variation

Some platforms pair CGM access with a registered dietitian; others rely entirely on app-driven coaching. The American Diabetes Association's Standards of Care in Diabetes 2024 recommends CGM use for all people with type 1 diabetes and for insulin-treated type 2 diabetes, but does not endorse CGM as standard of care for non-diabetic metabolic optimization. Subscribers using CGM outside a supervised clinical program should understand that the ADA guideline framework was not designed for their use case.

What Regulators and Clinicians Say

Physician opinions on direct-to-consumer CGM subscriptions vary considerably. Some endocrinologists support the concept because early glucose awareness may prompt dietary changes before prediabetes develops. Others argue that uninterpreted CGM data in low-risk individuals generates anxiety without actionable clinical benefit.

The Endocrine Society's 2022 position statement on CGM in non-intensive diabetes management acknowledges expanding CGM indications but stops short of recommending population-wide adoption in non-diabetic adults due to insufficient outcome data.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated in the ADA's 2023 press briefing on digital health tools: "The evidence for CGM in people without diabetes remains preliminary. We need randomized outcome data before we can make broad population recommendations." That reflects the current consensus among major professional societies.

The FDA's Center for Devices and Radiological Health (CDRH) has not issued specific guidance on CGM subscription models for non-diabetic consumers, but CDRH's general stance on direct-to-consumer wellness devices is that labeling claims must not exceed what the cleared device indication supports.

Practical Steps Before Subscribing to Levels or Any CGM Platform

Understanding the complaint field and regulatory context is useful, but consumers need actionable steps. The following checklist draws on FTC guidelines, FDA device rules, and state consumer-protection statutes.

Before You Sign Up

Check the BBB profile for open complaints and resolution rate. Search MAUDE for recent adverse events tied to the specific CGM sensor the platform uses. Verify the prescribing clinician's license through your state medical board. Confirm the subscription cancellation process in writing before paying.

During Your Subscription

Keep records of billing statements and all communications about cancellation. If you experience a skin reaction at the sensor site, file a MedWatch report at fda.gov/safety/medwatch and contact the device manufacturer directly. If glucose values seem inconsistent with how you feel, consult a licensed clinician rather than adjusting diet or medications based on app scores alone.

If You Have a Complaint

File with the BBB at bbb.org. File with the FTC at reportfraud.ftc.gov. File with your state attorney general if billing practices appear to violate state automatic-renewal law. If the complaint involves a prescribing clinician, file with your state medical board.